Top-selling diabetes drug continues to struggle: Novo Nordisk reports intermittent backorders worldwide
Higher-than-expected demand means that Novo Nordisk’s diabetes drug, Ozempic, is experiencing intermittent backorders of various doses worldwide, which is expected to continue for the rest of 2023.
It is not only in Denmark that Novo Nordisk continues to struggle to keep up with demand for its best-selling diabetes drug Ozempic, which in the first three months of the year alone sold for almost DKK 20bn (USD 3bn).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
